Related references
Note: Only part of the references are listed.Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Basic and Translational Concepts of Immune-Mediated Glomerular Diseases
William G. Couser
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
A novel pathogenetic concept-antiviral immunity in lupus nephritis
Adriana Migliorini et al.
NATURE REVIEWS NEPHROLOGY (2012)
Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis
C. Alejandro Arce-Salinas et al.
RHEUMATOLOGY INTERNATIONAL (2012)
IRF4 Deficiency Abrogates Lupus Nephritis Despite Enhancing Systemic Cytokine Production
Maciej Lech et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy
Dario Roccatello et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Assessment of a lupus nephritis cohort over a 30-year period
Sara C. Croca et al.
RHEUMATOLOGY (2011)
Safety and Efficacy of Rituximab in Systemic Lupus Erythematosus
Benjamin Terrier et al.
ARTHRITIS AND RHEUMATISM (2010)
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: Past, present, and future
Noam Jacob et al.
AUTOIMMUNITY (2010)
Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients
M. Garcia-Carrasco et al.
LUPUS (2010)
Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience
A. Lateef et al.
LUPUS (2010)
Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus
Fausta Catapano et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19
Ludovic Bacconnier et al.
RHEUMATOLOGY (2010)
A Retrospective Seven-Year Analysis of the Use of B Cell Depletion Therapy in Systemic Lupus Erythematosus at University College London Hospital: The First Fifty Patients
Tim Y-T. Lu et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome
Catherine Melander et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: the first case report from Indonesia
A. Mardjuadi et al.
CLINICAL RHEUMATOLOGY (2009)
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Gerald B. Appel et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Effects of rituximab on resistant SLE disease including lung involvement
J. A. Reynolds et al.
LUPUS (2009)
European consensus statement on the terminology used in the management of lupus glomerulonephritis
C. Gordon et al.
LUPUS (2009)
Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study
John N. Boletis et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
Ruth Pepper et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
Edmund K. Li et al.
RHEUMATOLOGY (2009)
Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy
Laurent Camous et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus
D. Albert et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Treatment of refractory SLE with rituximab plus cyclophosphamide:: clinical effects, serological changes, and predictors of response
T. Jonsdottir et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
Claudio Galarza et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2008)
Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus
G. Chehab et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2007)
The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials
MH Liang et al.
ARTHRITIS AND RHEUMATISM (2006)
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study
Monica Vigna-Perez et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
JE Gottenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab
H Tahir et al.
RHEUMATOLOGY (2005)
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand - An open-label trial
PP Sfikakis et al.
ARTHRITIS AND RHEUMATISM (2005)
The classification of glomerulonephritis in systemic lupus erythematosus revisited
JJ Weening et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus
K Manger et al.
ANNALS OF THE RHEUMATIC DISEASES (2002)
An open study of B lymphocyte depletion in systemic lupus erythematosus
MJ Leandro et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
